Pre-made Garetosmab benchmark antibody ( Whole mAb, anti-INHBA/ACT therapeutic antibody, Anti-EDF/FRP Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-234

Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-234-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody
INN Name Garetosmab
TargetACT
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions ActiveFibrodysplasia ossificans progressiva;Osteroporosis
Conditions DiscontinuedMusculoskeletal disorders
Development Techna